1
|
Olguín HC. The Gentle Side of the UPS: Ubiquitin-Proteasome System and the Regulation of the Myogenic Program. Front Cell Dev Biol 2022; 9:821839. [PMID: 35127730 PMCID: PMC8811165 DOI: 10.3389/fcell.2021.821839] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 12/30/2021] [Indexed: 12/12/2022] Open
Abstract
In recent years, the ubiquitin-proteasome system (UPS) has emerged as an important regulator of stem cell function. Here we review recent findings indicating that UPS also plays critical roles in the biology of satellite cells, the muscle stem cell responsible for its maintenance and regeneration. While we focus our attention on the control of key transcriptional regulators of satellite cell function, we briefly discuss early studies suggesting the UPS participates more broadly in the regulation of satellite cell stemness and regenerative capacity.
Collapse
|
2
|
Zaragoza-Ojeda M, Apatiga-Vega E, Arenas-Huertero F. Role of aryl hydrocarbon receptor in central nervous system tumors: Biological and therapeutic implications. Oncol Lett 2021; 21:460. [PMID: 33907570 PMCID: PMC8063300 DOI: 10.3892/ol.2021.12721] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2020] [Accepted: 01/25/2021] [Indexed: 12/12/2022] Open
Abstract
Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor, whose canonical pathway mainly regulates the genes involved in xenobiotic metabolism. However, it can also regulate several responses in a non-canonical manner, such as proliferation, differentiation, cell death and cell adhesion. AhR plays an important role in central nervous system tumors, as it can regulate several cellular responses via different pathways. The polymorphisms of the AHR gene have been associated with the development of gliomas. In addition, the metabolism of tumor cells promotes tumor growth, particularly in tryptophan synthesis, where some metabolites, such as kynurenine, can activate the AhR pathway, triggering cell proliferation in astrocytomas, medulloblastomas and glioblastomas. Furthermore, as part of the changes in neuroblastomas, AHR is able to downregulate the expression of proto-oncogene c-Myc, induce differentiation in tumor cells, and cause cell cycle arrest and apoptosis. Collectively, these data suggested that the modulation of the AhR pathway may downregulate tumor growth, providing a novel strategy for applications for the treatment of certain tumors through the control of the AhR pathway.
Collapse
Affiliation(s)
- Montserrat Zaragoza-Ojeda
- Laboratorio de Investigación en Patología Experimental, Hospital Infantil de México Federico Gómez, Mexico City 06720, México.,Posgrado en Ciencias Biológicas, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City 04510, México
| | - Elisa Apatiga-Vega
- Laboratorio de Investigación en Patología Experimental, Hospital Infantil de México Federico Gómez, Mexico City 06720, México
| | - Francisco Arenas-Huertero
- Laboratorio de Investigación en Patología Experimental, Hospital Infantil de México Federico Gómez, Mexico City 06720, México
| |
Collapse
|
3
|
Dou H, Duan Y, Zhang X, Yu Q, Di Q, Song Y, Li P, Gong Y. Aryl hydrocarbon receptor (AhR) regulates adipocyte differentiation by assembling CRL4B ubiquitin ligase to target PPARγ for proteasomal degradation. J Biol Chem 2019; 294:18504-18515. [PMID: 31653699 DOI: 10.1074/jbc.ra119.009282] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 10/16/2019] [Indexed: 12/17/2022] Open
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is the central regulator of adipogenesis, and its dysregulation is linked to obesity and metabolic diseases. Identification of the factors that regulate PPARγ expression and activity is therefore crucial for combating obesity. Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor with a known role in xenobiotic detoxification. Recent studies have suggested that AhR also plays essential roles in energy metabolism. However, the detailed mechanisms remain unclear. We previously reported that experiments with adipocyte-specific Cullin 4b (Cul4b)-knockout mice showed that CUL4B suppresses adipogenesis by targeting PPARγ. Here, using immunoprecipitation, ubiquitination, real-time PCR, and GST-pulldown assays, we report that AhR functions as the substrate receptor in CUL4B-RING E3 ubiquitin ligase (CRL4B) complex and is required for recruiting PPARγ. AhR overexpression reduced PPARγ stability and suppressed adipocyte differentiation, and AhR knockdown stimulated adipocyte differentiation in 3T3-L1 cells. Furthermore, we found that two lysine sites on residues 268 and 293 in PPARγ are targeted for CRL4B-mediated ubiquitination, indicating cross-talk between acetylation and ubiquitination. Our findings establish a critical role of AhR in regulating PPARγ stability and suggest that the AhR-PPARγ interaction may represent a potential therapeutic target for managing metabolic diseases arising from PPARγ dysfunction.
Collapse
Affiliation(s)
- Hao Dou
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Yuyao Duan
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Xiaohui Zhang
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Qian Yu
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Qian Di
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Yu Song
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Peishan Li
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China
| | - Yaoqin Gong
- The Key Laboratory of Experimental Teratology, Ministry of Education and Department of Molecular Medicine and Genetics, School of Basic Medical Sciences, Shandong University, Jinan, Shandong 250012, China.
| |
Collapse
|
4
|
Arenas-Huertero F, Zaragoza-Ojeda M, Sánchez-Alarcón J, Milić M, Šegvić Klarić M, Montiel-González JM, Valencia-Quintana R. Involvement of Ahr Pathway in Toxicity of Aflatoxins and Other Mycotoxins. Front Microbiol 2019; 10:2347. [PMID: 31681212 PMCID: PMC6798329 DOI: 10.3389/fmicb.2019.02347] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 09/26/2019] [Indexed: 12/18/2022] Open
Abstract
The purpose of this review is to present information about the role of activation of aflatoxins and other mycotoxins, of the aryl hydrocarbon receptor (AhR) pathway. Aflatoxins and other mycotoxins are a diverse group of secondary metabolites that can be contaminants in a broad range of agricultural products and feeds. Some species of Aspergillus, Alternaria, Penicilium, and Fusarium are major producers of mycotoxins, some of which are toxic and carcinogenic. Several aflatoxins are planar molecules that can activate the AhR. AhR participates in the detoxification of several xenobiotic substances and activates phase I and phase II detoxification pathways. But it is important to recognize that AhR activation also affects differentiation, cell adhesion, proliferation, and immune response among others. Any examination of the effects of aflatoxins and other toxins that act as activators to AhR must consider the potential of the disruption of several cellular functions in order to extend the perception thus far about the toxic and carcinogenic effects of these toxins. There have been no Reviews of existing data between the relation of AhR and aflatoxins and this one attempts to give information precisely about this dichotomy.
Collapse
Affiliation(s)
- Francisco Arenas-Huertero
- Experimental Pathology Research Laboratory, Children’s Hospital of Mexico Federico Gómez, Mexico, Mexico
| | - Montserrat Zaragoza-Ojeda
- Experimental Pathology Research Laboratory, Children’s Hospital of Mexico Federico Gómez, Mexico, Mexico
| | - Juana Sánchez-Alarcón
- Rafael Villalobos-Pietrini Laboratory of Genomic Toxicology and Environmental Chemistry, Faculty of Agrobiology, Autonomous University of Tlaxcala, Tlaxcala, Mexico
| | - Mirta Milić
- Mutagenesis Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia
| | - Maja Šegvić Klarić
- Department of Microbiology, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia
| | - José M. Montiel-González
- Rafael Villalobos-Pietrini Laboratory of Genomic Toxicology and Environmental Chemistry, Faculty of Agrobiology, Autonomous University of Tlaxcala, Tlaxcala, Mexico
| | - Rafael Valencia-Quintana
- Rafael Villalobos-Pietrini Laboratory of Genomic Toxicology and Environmental Chemistry, Faculty of Agrobiology, Autonomous University of Tlaxcala, Tlaxcala, Mexico
| |
Collapse
|
5
|
Yoo YM, Jung EM, Jeung EB. Rapamycin-induced autophagy decreases Myf5 and MyoD proteins in C2C12 myoblast cells. Toxicol In Vitro 2019; 58:132-141. [PMID: 30905858 DOI: 10.1016/j.tiv.2019.03.025] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 03/20/2019] [Accepted: 03/20/2019] [Indexed: 12/19/2022]
Abstract
Rapamycin is an immunosuppressant that inhibits the mammalian or mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in organisms including mice. Myf5 and MyoD act as muscle-specific transcriptional factors for skeletal muscle differentiation. In this study, we determined whether rapamycin-induced autophagy causes the decrease of Myf5 and MyoD protein in C2C12 myoblast cells. Rapamycin induced a significant increase in the expression of the microtubule-associated protein 1 light chain 3 (LC3) II protein in a dose-dependent manner for 12 h. Rapamycin treatment also significantly increased p-ERK, p-Akt, and catalase expressions, and decreased Mn-SOD expression in a dose-dependent manner. Bax expression was significantly high compared to Bcl-2 expression in a dose-dependent manner of rapamycin for 12 h. For further study of rapamycin-induced autophagy in C2C12 myoblast cells, we investigated rapamycin treatment for 24, 36, and 48 h. Cell viability did not change with rapamycin treatment for 24, 36, and 48 h. Rapamycin-induced LC3-II, Beclin-1, Bax, and Bcl-2 proteins were significantly increased compared to without rapamycin. p-ERK expression increased with rapamycin treatment for 24 and 36 h compared to that without rapamycin, but decreased for 48 h. p-Akt expression decreased with rapamycin treatment for 36 and 48 h compared to that without rapamycin. In the same conditions, rapamycin-induced autophagy significantly reduced the Myf5 and MyoD proteins. Together, these results suggest that rapamycin-induced autophagy results in the decrease of Myf5 and MyoD proteins in C2C12 myoblast cells.
Collapse
Affiliation(s)
- Yeong-Min Yoo
- Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
| | - Eui-Man Jung
- Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea
| | - Eui-Bae Jeung
- Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk 28644, Republic of Korea.
| |
Collapse
|
6
|
Mathur A, Pandey VK, Kakkar P. Activation of GSK3β/β-TrCP axis via PHLPP1 exacerbates Nrf2 degradation leading to impairment in cell survival pathway during diabetic nephropathy. Free Radic Biol Med 2018; 120:414-424. [PMID: 29655866 DOI: 10.1016/j.freeradbiomed.2018.04.550] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 03/27/2018] [Accepted: 04/11/2018] [Indexed: 01/06/2023]
Abstract
NF-E2 p45-related factor 2 (Nrf2), is a major redox sensitive transcription factor that plays an essential role in regulating glucose metabolism. Inactivation of Nrf2 has been associated with diabetic complications however, mechanisms warranting Nrf2 suppression are incompletely understood. We hypothesized that PHLPP1 activates GSK3β to induce β-TrCP mediated Nrf2 phosphorylation and degradation. In vivo study was carried out in STZ-NA induced type 2 diabetic male Wistar rats. GSK3β mediated Nrf2 ubiquitination was confirmed by administration of GSK3β inhibitor (LiCl; 60 mg/kg bwt.) which rapidly enhanced Nrf2 protein levels in STZ-NA treated diabetic rats. In addition, high glucose (30 mM; 48 h) treated renal proximal tubular cells NRK52E showed decreased Nrf2 nuclear localization, enhanced oxidative stress and caspase3 activation. While specific inhibition with GSK3β inhibitor SB216763 in vitro restored cellular homeostasis, glucose uptake and decreased apoptotic cell death. Immunoblotting and immunocytochemistry data demonstrated that aberrant renal glucose fluxes are associated with p53 mediated modulation in glucose transporter levels where expression of p53 is indirectly targeted through Nrf2 responsive MDM2 protein. Gene knockdown of PHLPP1 in NRK52E cells enhanced Nrf2-responsive antioxidant enzymes HO-1 and NQO-1 which suggested that PHLPP1 up-regulation during hyperglycemia lowers Nrf2 stability via GSK3β activation. More significantly, GSK3β inhibition enhanced Nrf2-ARE binding compared to diabetic rats, providing further confirmation for GSK3β/β-TrCP pathway in suppressing Nrf2 activation during diabetic renal injury. Taken together, our results indicate that PHLPP1 up-surged Nrf2 nuclear instability by promoting Nrf2/β-TrCP association and its inhibition may be critical in the management of diabetic nephropathy.
Collapse
Affiliation(s)
- Alpana Mathur
- Herbal Research Laboratory, Food, Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Babu Banarasi Das University, Lucknow, Uttar Pradesh, India
| | - Vivek Kumar Pandey
- Herbal Research Laboratory, Food, Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Academy of Scientific and Innovative Research, CSIR-IITR Campus, Lucknow, Uttar Pradesh, India
| | - Poonam Kakkar
- Herbal Research Laboratory, Food, Drug & Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Vishvigyan Bhawan 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India; Babu Banarasi Das University, Lucknow, Uttar Pradesh, India; Academy of Scientific and Innovative Research, CSIR-IITR Campus, Lucknow, Uttar Pradesh, India.
| |
Collapse
|
7
|
Calmodulin promotes matrix metalloproteinase 9 production and cell migration by inhibiting the ubiquitination and degradation of TBC1D3 oncoprotein in human breast cancer cells. Oncotarget 2018; 8:36383-36398. [PMID: 28422741 PMCID: PMC5482662 DOI: 10.18632/oncotarget.16756] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Accepted: 03/22/2017] [Indexed: 11/25/2022] Open
Abstract
The hominoid oncoprotein TBC1D3 enhances growth factor (GF) signaling and GF signaling, conversely, induces the ubiquitination and subsequent degradation of TBC1D3. However, little is known regarding the regulation of this degradation, and the role of TBC1D3 in the progression of tumors has also not been defined. In the present study, we demonstrated that calmodulin (CaM), a ubiquitous cellular calcium sensor, specifically interacted with TBC1D3 in a Ca2+-dependent manner and inhibited GF signaling-induced ubiquitination and degradation of the oncoprotein in both cytoplasm and nucleus of human breast cancer cells. The CaM-interacting site of TBC1D3 was mapped to amino acids 157~171, which comprises two 1–14 hydrophobic motifs and one lysine residue (K166). Deletion of these motifs was shown to abolish interaction between TBC1D3 and CaM. Surprisingly, this deletion mutation caused inability of GF signaling to induce the ubiquitination and subsequent degradation of TBC1D3. In agreement with this, we identified lysine residue 166 within the CaM-interacting motifs of TBC1D3 as the actual site for the GF signaling-induced ubiquitination using mutational analysis. Point mutation of this lysine residue exhibited the same effect on TBC1D3 as the deletion mutant, suggesting that CaM inhibits GF signaling-induced degradation of TBC1D3 by occluding its ubiquitination at K166. Notably, we found that TBC1D3 promoted the expression and activation of MMP-9 and the migration of MCF-7 cells. Furthermore, interaction with CaM considerably enhanced such effect of TBC1D3. Taken together, our work reveals a novel model by which CaM promotes cell migration through inhibiting the ubiquitination and degradation of TBC1D3.
Collapse
|
8
|
Yoo YM, Park YC. Data on MyoD reduction by autophagy in C2C12 cells. Data Brief 2017; 13:650-654. [PMID: 28725668 PMCID: PMC5502695 DOI: 10.1016/j.dib.2017.06.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Revised: 05/31/2017] [Accepted: 06/21/2017] [Indexed: 11/30/2022] Open
Abstract
Autophagy is a highly regulated physiologic mechanism in which cells maintain homeostasis by degrading excessive or unnecessary proteins and damaged or aged organelles through the lysosomal machinery (Yorimitsu and Klionsky, 2005) [1]. MyoD is basic helix-loop-helix (bHLH) transcription factors that regulate myoblast proliferation and myogenic differentiation. MyoD is expressed in adult skeletal muscle (Megeney et al., 1996) [2] and adult fibers (Brack et al., 2005) [3]. MyoD is mainly degraded by the ubiquitin-proteasome system (Floyd et al., 2001) [4] and partly by autophagy (Kim et al., 2012) [5]. Data showed that autophagy decreased MyoD protein in C2C12 cells by Western blotting analysis.
Collapse
Affiliation(s)
- Yeong-Min Yoo
- Department of Forest Environment Protection, College of Forest and Environmental Science, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea.,Institute of Forest Science, College of Forest and Environmental Science, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea
| | - Yung Chul Park
- Department of Forest Environment Protection, College of Forest and Environmental Science, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea.,Institute of Forest Science, College of Forest and Environmental Science, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea
| |
Collapse
|
9
|
Cirillo F, Resmini G, Ghiroldi A, Piccoli M, Bergante S, Tettamanti G, Anastasia L. Activation of the hypoxia‐inducible factor 1a promotes myogenesis through the noncanonical Wnt pathway, leading to hypertrophic myotubes. FASEB J 2017; 31:2146-2156. [DOI: 10.1096/fj.201600878r] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 01/23/2017] [Indexed: 01/11/2023]
Affiliation(s)
- Federica Cirillo
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Giulia Resmini
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Andrea Ghiroldi
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Marco Piccoli
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Sonia Bergante
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Guido Tettamanti
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
| | - Luigi Anastasia
- Laboratory of Stem Cells for Tissue EngineeringIstituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San DonatoMilanItaly
- Department of Biomedical Sciences for HealthUniversity of MilanMilanItaly
| |
Collapse
|
10
|
Kren NP, Zagon IS, McLaughlin PJ. Featured Article: Nuclear export of opioid growth factor receptor is CRM1 dependent. Exp Biol Med (Maywood) 2016; 241:273-81. [PMID: 26429201 PMCID: PMC4935446 DOI: 10.1177/1535370215605585] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Accepted: 08/18/2015] [Indexed: 01/11/2023] Open
Abstract
Opioid growth factor receptor (OGFr) facilitates growth inhibition in the presence of its specific ligand opioid growth factor (OGF), chemically termed [Met(5)]-enkephalin. The function of the OGF-OGFr axis requires the receptor to translocate to the nucleus. However, the mechanism of nuclear export of OGFr is unknown. In this study, endogenous OGFr, as well as exogenously expressed OGFr-EGFP, demonstrated significant nuclear accumulation in response to leptomycin B (LMB), an inhibitor of CRM1-dependent nuclear export, suggesting that OGFr is exported in a CRM1-dependent manner. One consensus sequence for a nuclear export signal (NES) was identified. Mutation of the associated leucines, L217 L220 L223 and L225, to alanine resulted in decreased nuclear accumulation. NES-EGFP responded to LMB, indicating that this sequence is capable of functioning as an export signal in isolation. To determine why the sequence functions differently in isolation than as a full length protein, the localization of subNES was evaluated in the presence and absence of MG132, a potent inhibitor of proteosomal degradation. MG132 had no effect of subNES localization. The role of tandem repeats located at the C-terminus of OGFr was examined for their role in nuclear trafficking. Six of seven tandem repeats were removed to form deltaTR. DeltaTR localized exclusively to the nucleus indicating that the tandem repeats may contribute to the localization of the receptor. Similar to the loss of cellular proliferation activity (i.e. inhibition) recorded with subNES, deltaTR also demonstrated a significant loss of inhibitory activity indicating that the repeats may be integral to receptor function. These experiments reveal that OGFr contains one functional NES, L217 L220 L223 and L225 and can be exported from the nucleus in a CRM1-dependent manner.
Collapse
Affiliation(s)
- Nancy P Kren
- Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, PA, USA
| | - Ian S Zagon
- Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, PA, USA
| | - Patricia J McLaughlin
- Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, PA, USA
| |
Collapse
|
11
|
Grabiec K, Milewska M, Błaszczyk M, Gajewska M, Grzelkowska-Kowalczyk K. Palmitate exerts opposite effects on proliferation and differentiation of skeletal myoblasts. Cell Biol Int 2015; 39:1044-52. [PMID: 25857830 DOI: 10.1002/cbin.10477] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Accepted: 03/31/2015] [Indexed: 12/27/2022]
Abstract
The purpose of the study was to examine mechanisms controlling cell cycle progression/arrest and differentiation of mouse C2C12 myoblasts exposed to long-chain saturated fatty acid salt, palmitate. Treatment of proliferating myoblasts with palmitate (0.1 mmol/l) markedly decreased myoblast number. Cyclin A and cyclin D1 levels decreased, whereas total p21 and p21 complexed with cyclin-dependent kinase-4 (cdk4) increased in myoblasts treated with palmitate. In cells induced to differentiation addition of palmitate augmented the level of cyclin D3, the early (myogenin) and late (α-actinin, myosin heavy chain) markers of myogenesis, and caused an increase of myotube diameter. In conclusion, exposure to palmitate inhibits proliferation of myoblasts through a decrease in cyclin A and cyclin D1 levels and an increase of p21-cdk4 complex formation; however, it promotes cell cycle exit, myogenic differentiation and myotube growth.
Collapse
Affiliation(s)
- Kamil Grabiec
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776, Warsaw, Poland
| | - Marta Milewska
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776, Warsaw, Poland
| | - Maciej Błaszczyk
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776, Warsaw, Poland
| | - Małgorzata Gajewska
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776, Warsaw, Poland
| | - Katarzyna Grzelkowska-Kowalczyk
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776, Warsaw, Poland
| |
Collapse
|
12
|
Grabiec K, Gajewska M, Milewska M, Błaszczyk M, Grzelkowska-Kowalczyk K. The influence of high glucose and high insulin on mechanisms controlling cell cycle progression and arrest in mouse C2C12 myoblasts: the comparison with IGF-I effect. J Endocrinol Invest 2014; 37:233-45. [PMID: 24615360 PMCID: PMC3949044 DOI: 10.1007/s40618-013-0007-z] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2013] [Accepted: 11/17/2013] [Indexed: 01/03/2023]
Abstract
BACKGROUND Myogenesis is susceptible to the availability of nutrients and humoral factors and suboptimal fetal environments affect the number of myofibers and muscle mass. AIM We examined the mechanisms regulating cell cycle progression and arrest in skeletal myoblasts. MATERIALS AND METHODS Mouse C2C12 myoblasts were subjected to proliferation or induction of differentiation in the presence of high glucose and high insulin (HGHI glucose 15 mmol/l, insulin 50 nmol/l), and these effects were compared with the influence of anabolic factor for skeletal muscle, insulin-like growth factor-I (IGF-I 30 nmol/l). RESULTS High glucose and high insulin, similarly to IGF-I, increased the intracellular level of cyclin A, cyclin B1 and cyclin D1 during myoblast proliferation. In HGHI-treated myoblasts, these cyclins were localized mostly in the nuclei, and the level of cdk4-bound cyclin D1 was augmented. HGHI significantly stimulated the expression of cyclin D3, total level of p21 and cdk-bound fraction of p21 in differentiating cells. The cellular level of MyoD was augmented by HGHI both in proliferating and differentiating myogenic cells. CONCLUSIONS High glucose and insulin modify the mechanisms controlling cell cycle progression and the onset of myogenesis by: (1) increase of cyclin A, cyclin B1 and cyclin D1 in myoblast nuclei, and stimulation of cyclin D1-cdk4 binding; (2) increase in cyclin D3 and MyoD levels, and the p21-cdk4 complexes after induction of differentiation. Hyperglycemia/hyperinsulinemia during fetal or postnatal life could exert effects similar to IGF-I and can be, therefore, favourable for skeletal muscle growth and regeneration.
Collapse
Affiliation(s)
- K. Grabiec
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland
| | - M. Gajewska
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland
| | - M. Milewska
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland
| | - M. Błaszczyk
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland
| | - K. Grzelkowska-Kowalczyk
- Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences (SGGW), Nowoursynowska 159, 02-776 Warsaw, Poland
| |
Collapse
|
13
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- #] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
14
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 and 1880=1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
15
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- -] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
16
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- #] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
17
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- gadu] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
18
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 1-- -] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
19
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden Syndrome-Related Mutations in PTEN Associate with Enhanced Proteasome Activity. Cancer Res 2013. [DOI: 10.1158/0008-5472.can-12-3811 order by 8029-- awyx] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
Abstract
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes. Cancer Res; 73(10); 3029–40. ©2013 AACR.
Collapse
Affiliation(s)
- Xin He
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Nicholas Arrotta
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Deepa Radhakrishnan
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Yu Wang
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Todd Romigh
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| | - Charis Eng
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
- Authors' Affiliations: 1Genomic Medicine Institute, 2Taussig Cancer Institute, and 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; and 4Department of Genetics and Genome Sciences, and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
| |
Collapse
|
20
|
He X, Arrotta N, Radhakrishnan D, Wang Y, Romigh T, Eng C. Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity. Cancer Res 2013; 73:3029-40. [PMID: 23475934 DOI: 10.1158/0008-5472.can-12-3811] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Germline mutations in PTEN have been described in a spectrum of syndromes that are collectively known as PTEN hamartoma tumor syndrome (PHTS). In addition to being mutated in the germline in PHTS, somatic loss-of-function PTEN mutations are seen in a wide range of sporadic human tumors. Here, we show evidence of upregulated proteasome activity in PHTS-derived lymphoblasts, Pten knock-in mice and cell lines expressing missense and nonsense PTEN mutations. Notably, elevated nuclear proteasome activity occurred in cells expressing the nuclear mislocalized PTEN-K62R mutant, whereas elevated cytosolic proteasome activity was observed in cells expressing the cytosolic-predominant mutant PTEN (M3M4 and C136R). Treatment with proteasome inhibitor MG-132 was able to restore both nonsense and missense mutant PTEN protein levels in vitro. PHTS patients with destabilizing PTEN mutations and proteasome hyperactivity are more susceptible to develop neurologic symptoms such as mental retardation and autism than mutation-positive patients with normal proteasome activity. A detailed molecular and functional analysis shows that PTEN mutants most likely cause proteasome hyperactivity via 2 different mechanisms, namely, induction of proteotoxic stress and loss of protein phosphatase activity. These results provide novel insights into the cellular functions of PTEN and reveal molecular mechanisms whereby PTEN mutations increase proteasome activity and lead to neurologic phenotypes.
Collapse
Affiliation(s)
- Xin He
- Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA
| | | | | | | | | | | |
Collapse
|
21
|
Gui J, Li Z, Zhou X. Dynamic change of TNIK in response to tumor necrosis factor alpha in a TRAF2-dependent manner. Hum Cell 2013; 26:67-72. [PMID: 23355318 DOI: 10.1007/s13577-012-0058-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Accepted: 12/28/2012] [Indexed: 11/25/2022]
Abstract
TNIK (TRAF2- and NCK-interacting kinase) was named because of its association with TRAF2 (tumor necrosis factor receptor-associated factor 2). But the relationship between TNIK and TRAF2 is still elusive, in addition to which the involvement of TNIK in JNK activation by TNFα hints that there maybe a linkage between TNIK and TRAF2. In this work, we illustrated that TNIK protein levels were dynamic in response to TNFα stimulation in an ubiquitin-dependent manner. Further study showed that TRAF2 negatively modulated the levels of TNIK by regulating the ubiquitin conjugation. In conclusion, our data may give evidence that dynamic change of TNIK offers a way to protect cells from outside stimulus.
Collapse
Affiliation(s)
- Jinghua Gui
- Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Mailbox 539, Hangzhou 310018, Zhejiang, People's Republic of China
| | | | | |
Collapse
|
22
|
Kim CH, Kim KH, Yoo YM. Melatonin-induced autophagy is associated with degradation of MyoD protein in C2C12 myoblast cells. J Pineal Res 2012; 53:289-97. [PMID: 22582971 DOI: 10.1111/j.1600-079x.2012.00998.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
MyoD is a muscle-specific transcriptional factor that acts as a master switch for skeletal muscle differentiation. This protein regulates myoblast proliferation and myogenic differentiation and is also a short-lived regulatory protein that is degraded by the ubiquitin system. However, the lysosomal pathway of MyoD protein degradation remains unknown. In this study, we sought to determine whether melatonin (1, 2mm)-induced autophagy causes the degradation of MyoD protein in C2C12 myoblast cells. Melatonin induced a significant increase in expression of the microtubule-associated protein 1 light chain 3 (LC3)-II and Beclin-1 proteins in a dose-dependent manner. Melatonin treatment also significantly increased p-ERK, Ras, and p-Akt expressions in a dose-dependent manner. However, Bax expression was high compared with the absence of melatonin treatment, and Bcl-2 expression was high in the 0.1-0.5mm melatonin treatments and low in the 1 and 2mm melatonin treatments. Under the same conditions, cytosolic MyoD protein was significantly decreased in a dose-dependent manner and completely eliminated by 36hr. This decrease in MyoD protein involved ubiquitin-mediated proteasomal activity with proteasome inhibitor MG132 or autophagy-dependent lysosomal degradation with lysosomal inhibitor bafilomycin A1 (Baf-A1). In the same condition, phosphorylation of the mammalian target of rapamycin, p-mTOR, and p-S6K expression with Baf-A1 or Baf-A1-plus melatonin treatment were significantly decreased compared with the levels after treatment with melatonin only. Together, these results suggest that melatonin (1, 2mm)-induced autophagy results in partial lysosomal degradation of MyoD protein in C2C12 myoblast cells.
Collapse
Affiliation(s)
- Chi Hyun Kim
- Department of Biomedical Engineering, College of Health Science, Yonsei University, Wonju, Gangwon-do, Korea
| | | | | |
Collapse
|
23
|
Transformation by E1A oncoprotein involves ubiquitin-mediated proteolysis of the neuronal and tumor repressor REST in the nucleus. J Virol 2012; 86:5594-602. [PMID: 22419809 DOI: 10.1128/jvi.06811-11] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The adenovirus early region 1A (E1A) protein promotes cell immortalization and transformation by mediating the activities of key cellular regulators. The repressor element 1-silencing transcription factor (REST), which is a major neuronal and tumor suppressor, was previously found mainly in the cytoplasm rather than in the nuclei of adenovirus-transformed rodent cells (22). We now demonstrate that the loss of REST in the nucleus is due to its rapid degradation by the ubiquitin-proteasome system. Only nuclear REST, but not its cytoplasmic counterpart, was ubiquitinated and degraded. REST degradation was blocked by the ubiquitination inhibitor PYR-41 and the proteasome inhibitor MG-132 but not by the nuclear export inhibitor leptomycin B. REST degradation required both of its two C-terminal degrons that are recognized by the ubiquitin ligase SCF(β-TrCP), since deletion or mutation of either degron eliminated degradation. Importantly, E1A was shown to mediate REST ubiquitination and degradation by upregulating β-TrCP. Knockdown of E1A in virus-transformed cells reduced both β-TrCP and ubiquitination of nuclear REST. In contrast, when expressed in HeLa cells, E1A enhanced the degradation of nuclear REST. Reconstitution of REST in virus-transformed cells negatively affected E1A-mediated cell proliferation and anchorage-independent growth. These data strongly indicate that E1A stimulates ubiquitination and proteolysis of REST in the nucleus, thereby abolishing the tumor suppressor functions of REST.
Collapse
|
24
|
Biswas M, Phan D, Watanabe M, Chan JY. The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysis. J Biol Chem 2011; 286:39282-9. [PMID: 21953459 DOI: 10.1074/jbc.m111.253807] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
Nuclear factor E2-related factor 1 (Nrf1) is a basic leucine zipper transcription factor that plays important roles in cellular stress response and development. Currently, the mechanism regulating Nrf1 expression is poorly understood. We report here that Nrf1 is a short-lived protein that is targeted by F-box protein Fbw7, which is the substrate-specifying component of SCF (Skp1-Cul1-Fbox protein-Rbx1)-type ubiquitin ligase for degradation via the ubiquitin-proteasome pathway. We show that Fbw7 directly binds Nrf1 through a Cdc4 phosphodegron and that enforced expression of Fbw7 promotes the ubiquitination and degradation of Nrf1. Conversely, depletion of endogenous Fbw7 leads to decreased Nrf1 ubiquitination and accumulation of Nrf1 protein. Accordingly, expression of Fbw7 leads to down-regulation of antioxidant response element-driven gene activation, whereas disruption of Fbw7-mediated destabilization of Nrf1 leads to increased antioxidant response element-driven gene expression. Together, these data identify Fbw7 as a regulator of Nrf1 expression and reveal a novel function of Fbw7 in cellular stress response.
Collapse
Affiliation(s)
- Madhurima Biswas
- Department of Laboratory Medicine and Pathology, University of California, Irvine, California 92697, USA
| | | | | | | |
Collapse
|
25
|
Secretome Analysis of Skeletal Myogenesis Using SILAC and Shotgun Proteomics. INTERNATIONAL JOURNAL OF PROTEOMICS 2011; 2011:329467. [PMID: 22084683 PMCID: PMC3200090 DOI: 10.1155/2011/329467] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2010] [Accepted: 01/26/2011] [Indexed: 12/18/2022]
Abstract
Myogenesis, the formation of skeletal muscle, is a multistep event that commences with myoblast proliferation, followed by cell-cycle arrest, and finally the formation of multinucleated myotubes via fusion of mononucleated myoblasts. Each step is orchestrated by well-documented intracellular factors, such as cytoplasmic signalling molecules and nuclear transcription factors. Regardless, the key step in getting a more comprehensive understanding of the regulation of myogenesis is to explore the extracellular factors that are capable of eliciting the downstream intracellular factors. This could further provide valuable insight into the acute cellular response to extrinsic cues in maintaining normal muscle development. In this paper, we survey the intracellular factors that respond to extracellular cues that are responsible for the cascades of events during myogenesis: myoblast proliferation, cell-cycle arrest of myoblasts, and differentiation of myoblasts into myotubes. This focus on extracellular perspective of muscle development illustrates our mass spectrometry-based proteomic approaches to identify differentially expressed secreted factors during skeletal myogenesis.
Collapse
|
26
|
Chan CYX, Masui O, Krakovska O, Belozerov VE, Voisin S, Ghanny S, Chen J, Moyez D, Zhu P, Evans KR, McDermott JC, Siu KWM. Identification of differentially regulated secretome components during skeletal myogenesis. Mol Cell Proteomics 2011; 10:M110.004804. [PMID: 21343469 DOI: 10.1074/mcp.m110.004804] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Myogenesis is a well-characterized program of cellular differentiation that is exquisitely sensitive to the extracellular milieu. Systematic characterization of the myogenic secretome (i.e. the ensemble of secreted proteins) is, therefore, warranted for the identification of novel secretome components that regulate both the pluripotency of these progenitor mesenchymal cells, and also their commitment and passage through the differentiation program. Previously, we have successfully identified 26 secreted proteins in the mouse skeletal muscle cell line C2C12 (1). In an effort to attain a more comprehensive picture of the regulation of myogenesis by its extracellular milieu, quantitative profiling employing stable isotope labeling by amino acids in cell culture was implemented in conjunction with two parallel high throughput online reverse phase liquid chromatography-tandem mass spectrometry systems. In summary, 34 secreted proteins were quantified, 30 of which were shown to be differentially expressed during muscle development. Intriguingly, our analysis has revealed several novel up- and down-regulated secretome components that may have critical biological relevance for both the maintenance of pluripotency and the passage of cells through the differentiation program. In particular, the altered regulation of secretome components, including follistatin-like protein-1, osteoglycin, spondin-2, and cytokine-induced apoptosis inhibitor-1, along with constitutively expressed factors, such as fibulin-2, illustrate dynamic changes in the secretome that take place when differentiation to a specific lineage occurs.
Collapse
Affiliation(s)
- C Y X'avia Chan
- Department of Biology, York University, 4700 Keele Street, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Chiribau CB, Gaccioli F, Huang CC, Yuan CL, Hatzoglou M. Molecular symbiosis of CHOP and C/EBP beta isoform LIP contributes to endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol 2010; 30:3722-31. [PMID: 20479126 PMCID: PMC2897554 DOI: 10.1128/mcb.01507-09] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Revised: 01/19/2010] [Accepted: 05/05/2010] [Indexed: 11/20/2022] Open
Abstract
Induction of the transcription factor CHOP (CCAAT-binding homologous protein; GADD 153) is a critical cellular response for the transcriptional control of endoplasmic reticulum (ER) stress-induced apoptosis. Upon nuclear translocation, CHOP upregulates the transcription of proapoptotic factors and downregulates antiapoptotic genes. Transcriptional activation by CHOP involves heterodimerization with other members of the basic leucine zipper transcription factor (bZIP) family. We show that the bZIP protein C/EBP beta isoform LIP is required for nuclear translocation of CHOP during ER stress. In early ER stress, LIP undergoes proteasomal degradation in the cytoplasmic compartment. During later ER stress, LIP binds CHOP in both cytoplasmic and nuclear compartments and contributes to its nuclear import. By using CHOP-deficient cells and transfections of LIP-expressing vectors in C/EBP beta(-/-) mouse embryonic fibroblasts (MEFs), we show that the LIP-CHOP interaction has a stabilizing role for LIP. At the same time, CHOP uses LIP as a vehicle for nuclear import. LIP-expressing C/EBP beta(-/-) MEFs showed enhanced ER stress-induced apoptosis compared to C/EBP beta-null cells, a finding in agreement with the decreased levels of Bcl-2, a known transcriptional control target of CHOP. In view of the positive effect of CHOP-LIP interaction in mediating their proapoptotic functions, we propose this functional cooperativity as molecular symbiosis between proteins.
Collapse
Affiliation(s)
- Calin-Bogdan Chiribau
- Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
| | - Francesca Gaccioli
- Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
| | - Charlie C. Huang
- Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
| | - Celvie L. Yuan
- Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
| | - Maria Hatzoglou
- Department of Nutrition, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106
| |
Collapse
|
28
|
The N-terminal domain of MyoD is necessary and sufficient for its nuclear localization-dependent degradation by the ubiquitin system. Proc Natl Acad Sci U S A 2008; 105:15690-5. [PMID: 18836078 DOI: 10.1073/pnas.0808373105] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
A growing number of proteins, including the myogenic transcription factor MyoD, are targeted for proteasomal degradation after N-terminal ubiquitination (NTU) where the first ubiquitin moiety is conjugated to the N-terminal residue rather than to an internal lysine. NTU might be essential in targeting both lysine-containing and naturally occurring lysine-less proteins such as p16(INK4a) and p14(ARF); however, the mechanisms that underlie this process are largely unknown. Specifically, the recognition motif(s) in the target substrates and the ubiquitin ligase(s) that catalyze NTU are still obscure. Here we show that the N-terminal domain of MyoD is critical for its degradation and that its destabilizing effect depends on nuclear localization of the protein. Deletion of the first 15 aa of MyoD blocked completely its lysine-independent degradation. Importantly, transfer of the first 30 N-terminal residues of MyoD to GFP destabilized this otherwise stable protein, and, here too, targeting for degradation depended on localization of the protein to the nucleus. Deletion of the N-terminal domain of lysine-less MyoD did not abolish completely ubiquitination of the protein, suggesting that this domain may be required for targeting the protein also in a postubiquitination step. Interestingly, NTU is evolutionarily conserved: in the yeast Saccharomyces cerevisiae lysine-less (LL) MyoD is degraded in a ubiquitin-, N-terminal domain-, and nuclear localization-dependent manner. Taken together, our data suggest that a short N-terminal segment of MyoD is necessary and sufficient to render MyoD susceptible for ubiquitin- and nuclear-dependent degradation.
Collapse
|
29
|
Lingbeck JM, Trausch-Azar JS, Ciechanover A, Schwartz AL. In vivo interactions of MyoD, Id1, and E2A proteins determined by acceptor photobleaching fluorescence resonance energy transfer. FASEB J 2008; 22:1694-701. [PMID: 18198216 DOI: 10.1096/fj.07-095000] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
MyoD, a skeletal muscle transcription factor, is rapidly degraded by the ubiquitin-proteasome system. MyoD interacts with ubiquitously expressed E2A or inhibitor of DNA binding (Id) proteins to activate or inhibit transcription, respectively. Furthermore, MyoD has been shown to modulate the ubiquitin-mediated degradation of Id1 and E2A proteins, E12 and E47. The molecular mechanisms governing these events are not clear but are hypothesized to occur via heterodimer formation. Fluorescence resonance energy transfer (FRET) is a technique for evaluation of protein-protein interactions in vivo. Using acceptor photobleaching FRET and chimeric proteins composed of MyoD, Id1, E12, E47, E12(NLS), or MyoD(NLS) and either cyan fluorescent protein or yellow fluorescent protein, we show that each of the wild-type proteins is capable of homodimerization. In addition, heterodimers form between Id1 and E2A proteins, as well as between MyoD and E2A proteins. The Id1:E2A interaction is stronger than the MyoD:E2A interaction, which is consistent with the notion that inhibition of MyoD action occurs by the sequestration of E2A proteins by Id. The stronger interaction of Id1 with E2A may also explain the decrease in the rate of ubiquitin-proteasome degradation of Id1 that is significantly greater than that of MyoD when E2A proteins are abundant. Thus, these studies extend our understanding of the molecular mechanisms of MyoD action.
Collapse
Affiliation(s)
- Jody M Lingbeck
- Edward Mallinckrodt Department of Pediatrics and Molecular Biology and Pharmacology, Washington University School of Medicine and St. Louis Children's Hospital, St. Louis, Missouri 63110, USA
| | | | | | | |
Collapse
|
30
|
Lamour V, Detry C, Sanchez C, Henrotin Y, Castronovo V, Bellahcène A. Runx2- and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J Biol Chem 2007; 282:36240-9. [PMID: 17956871 DOI: 10.1074/jbc.m705833200] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Bone sialoprotein (BSP) is a bone matrix glycoprotein whose expression coincides with terminal osteoblastic differentiation and the onset of mineralization. In this study we show that BSP expression is considerably increased in confluent Saos-2 human osteosarcoma cells and in differentiating normal human osteoblasts, concomitantly with the decrease of Runx2, a key transcription factor controlling bone formation. Therefore, we investigated the role of Runx2 in the regulation of BSP expression in Saos-2 cells. Using a mobility shift assay, we demonstrated that Runx2 binds to the BSP promoter only in preconfluent cells. Histone deacetylase 3 (HDAC3) has been recently shown to act as a Runx2 co-repressor. Chromatin immunoprecipitation assays demonstrated that both Runx2 and HDAC3 are detectable at the BSP promoter in preconfluent Saos-2 cells but not when they are confluent and overexpress BSP. Consistently, nuclear Runx2 protein level is down-regulated, whereas Saos-2 cells became increasingly confluent. Finally, the suppression of HDAC3, Runx2, or both by RNA interference induced the expression of BSP at both mRNA and protein levels in Saos-2 cells. Our data demonstrate that Runx2 and HDAC3 repress BSP gene expression and that this repression is suspended upon osteoblastic cell differentiation. Both the nuclear disappearance of Runx2 and the non-recruitment of HDAC3 represent new means to relieve Runx2-mediated suppression of BSP expression, thus allowing the acquisition of a fully differentiated and mineralization-competent phenotype by osteoblast cells.
Collapse
Affiliation(s)
- Virginie Lamour
- Metastasis Research Laboratory, Center of Experimental Cancer Research and Bone and Cartilage Metabolism Research Unit, University of Liège, 4000 Liège, Belgium
| | | | | | | | | | | |
Collapse
|
31
|
Olguin HC, Yang Z, Tapscott SJ, Olwin BB. Reciprocal inhibition between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. ACTA ACUST UNITED AC 2007; 177:769-79. [PMID: 17548510 PMCID: PMC2064278 DOI: 10.1083/jcb.200608122] [Citation(s) in RCA: 208] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Postnatal growth and regeneration of skeletal muscle requires a population of resident myogenic precursors named satellite cells. The transcription factor Pax7 is critical for satellite cell biogenesis and survival and has been also implicated in satellite cell self-renewal; however, the underlying molecular mechanisms remain unclear. Previously, we showed that Pax7 overexpression in adult primary myoblasts down-regulates MyoD and prevents myogenin induction, inhibiting myogenesis. We show that Pax7 prevents muscle differentiation independently of its transcriptional activity, affecting MyoD function. Conversely, myogenin directly affects Pax7 expression and may be critical for Pax7 down-regulation in differentiating cells. Our results provide evidence for a cross-inhibitory interaction between Pax7 and members of the muscle regulatory factor family. This could represent an additional mechanism for the control of satellite cell fate decisions resulting in proliferation, differentiation, and self-renewal, necessary for skeletal muscle maintenance and repair.
Collapse
Affiliation(s)
- Hugo C Olguin
- Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA
| | | | | | | |
Collapse
|
32
|
Depaux A, Regnier-Ricard F, Germani A, Varin-Blank N. A crosstalk between hSiah2 and Pias E3-ligases modulates Pias-dependent activation. Oncogene 2007; 26:6665-76. [PMID: 17533377 DOI: 10.1038/sj.onc.1210486] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Protein inhibitor of activated STAT (Pias) and human homologues of seven in absentia (hSiah) proteins both exhibit properties of ubiquitin-family peptides conjugating enzymes. Pias present E3-ligase activity for small ubiquitin-related modifiers (Sumo) covalent attachment to their targets. This post-translational modification is responsible for the activation of different transcription factors such as AP1. HSiah proteins possess ubiquitin-E3-ligase activity that triggers their partners to proteasomal-dependent degradation. The present study identifies Pias as a new hSiah2-interacting protein. We demonstrate that hSiah2 regulates specifically the proteasome-dependent degradation of Pias proteins. On reverse, Pias does not prevent hSiah2 degradation. We provide evidences for hSiah2-dependent degradation of Pias as being a mechanism in the regulation of c-jun N-terminal kinase-activating pathways. This report describes a new interconnection between sumoylation and ubiquitination pathways by regulating the levels of the E3-ligases available for these processes.
Collapse
Affiliation(s)
- A Depaux
- Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris, France
| | | | | | | |
Collapse
|
33
|
Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007; 8:584-91. [PMID: 17468759 DOI: 10.1038/ni1464] [Citation(s) in RCA: 242] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2007] [Accepted: 04/05/2007] [Indexed: 11/08/2022]
Abstract
Activation of transcription factor NF-kappaB in the innate immune system is tightly regulated to prevent excessive inflammatory responses. How NF-kappaB activation is terminated, however, is not fully understood. Here we report that PDLIM2 negatively regulated NF-kappaB activity, acting as a nuclear ubiquitin E3 ligase targeting the p65 subunit of NF-kappaB. PDLIM2 bound to p65 and promoted p65 polyubiquitination. In addition, PDLIM2 targeted p65 to discrete intranuclear compartments where polyubiquitinated p65 was degraded by the proteasome. PDLIM2 deficiency resulted in larger amounts of nuclear p65, defective p65 ubiquitination and augmented production of proinflammatory cytokines in response to innate stimuli. Our findings delineate a pathway by which PDLIM2 terminates NF-kappaB activation through intranuclear sequestration and subsequent degradation.
Collapse
Affiliation(s)
- Takashi Tanaka
- Laboratory for Host Defense, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa 230-0045, Japan
| | | | | |
Collapse
|
34
|
Li C, Wu RC, Amazit L, Tsai SY, Tsai MJ, O'Malley BW. Specific amino acid residues in the basic helix-loop-helix domain of SRC-3 are essential for its nuclear localization and proteasome-dependent turnover. Mol Cell Biol 2007; 27:1296-308. [PMID: 17158932 PMCID: PMC1800725 DOI: 10.1128/mcb.00336-06] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2006] [Revised: 04/26/2006] [Accepted: 11/22/2006] [Indexed: 12/21/2022] Open
Abstract
SRC-3/AIB1/ACTR/pCIP/RAC3/TRAM-1 is a primary transcriptional coactivator for the estrogen receptor. Here we report that deletion of the SRC-3 basic helix-loop-helix (bHLH) domain blocks its proteasome-dependent turnover. We further identified two residues (K17 and R18) in the SRC-3 bHLH domain that are essential for its stability. Moreover, we found that the bHLH domain contains a bipartite nuclear localization signal (NLS). SRC-3 NLS mutants block its translocation into the nucleus, and this correlates with its insensitivity to proteasome-dependent turnover. SRC-3 shows a time-dependent decay in the presence of cycloheximide which is not apparent for the cytoplasmic mutant. Fusion of a simian virus 40 T antigen NLS to the cytoplasmic localized SRC-3 mutant drives it back into the nucleus and restores its proteasomal sensitivity. In addition, the cytoplasmic mutants are inactive for transcriptional coactivation and cancer cell growth. Taken together, our data indicate that proteasome-dependent turnover of SRC-3 occurs in the nucleus and that two amino acid residues in the bHLH domain provide a signal for its nuclear localization and proteasome-dependent degradation as well as for regulation of SRC-3 transcriptional coactivator capacity.
Collapse
Affiliation(s)
- Chao Li
- Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
35
|
Ye X, Liu SF. Lipopolysaccharide causes Sp1 protein degradation by inducing a unique trypsin-like serine protease in rat lungs. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2006; 1773:243-53. [PMID: 17092579 DOI: 10.1016/j.bbamcr.2006.09.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2006] [Revised: 08/19/2006] [Accepted: 09/05/2006] [Indexed: 12/20/2022]
Abstract
We have previously demonstrated that challenge of rat or mice with lipopolysaccharide (LPS) in vivo promotes Sp1 protein degradation. The protease responsible for the LPS-induced Sp1 degradation has not been identified. In this study, we have identified, characterized and partially purified an LPS-inducible Sp1-degrading enzyme (LISPDE) activity from rat lungs. LISPDE activity selectively degraded Sp1, but not nuclear protein, C-fos, p65, I-kappaBalpha and protein actin. Nuclear extract contains approximately 14-fold of the LISPDE activity as that detected in cytoplasmic extract, suggesting that LISPDE is predominantly a nuclear protease. Using biochemical reagents, protease inhibitors and peptide substrates, we have characterized the LISPDE activity. Based on biochemical characteristics, inhibitor profile, and substrate specificity, we have shown that LISPDE activity is not 26S proteasome, caspase or cathepsin-like activity, but is a trypsin-like serine protease activity. Using soybean trypsin inhibitor (SBTI)-sepharose affinity column, we have partially purified the LISPDE protein, which has an estimated molecular mass of 33 kDa and selectively degrades native Sp1 protein. We mapped the initial site for proteolytic cleavage of Sp1 by LISPDE to be located within the region between amino acids 181-328. We conclude that LPS causes Sp1 degradation by inducing a unique trypsin-like serine protease, LISPDE.
Collapse
Affiliation(s)
- Xiaobing Ye
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Long Island Jewish Medical Center, The Long Island Campus for the Albert Einstein College of Medicine, Research Building, RM B371, 270-05 76th Avenue, New Hyde Park, NY 11040, USA
| | | |
Collapse
|
36
|
Zheng X, Ruas JL, Cao R, Salomons FA, Cao Y, Poellinger L, Pereira T. Cell-type-specific regulation of degradation of hypoxia-inducible factor 1 alpha: role of subcellular compartmentalization. Mol Cell Biol 2006; 26:4628-41. [PMID: 16738327 PMCID: PMC1489139 DOI: 10.1128/mcb.02236-05] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a transcription factor that mediates adaptive cellular responses to decreased oxygen availability (hypoxia). At normoxia, HIF-1 alpha is targeted by the von Hippel-Lindau tumor suppressor protein (pVHL) for degradation by the ubiquitin-proteasome pathway. In the present study we have observed distinct cell-type-specific differences in the ability of various tested pVHL-interacting subfragments to stabilize HIF-1 alpha and unmask its function at normoxia. These properties correlated with differences in subcellular compartmentalization and degradation of HIF-1 alpha. We observed that the absence or presence of nuclear localization or export signals differently affected the ability of a minimal HIF-1 alpha peptide spanning residues 559 to 573 of mouse HIF-1 alpha to stabilize endogenous HIFalpha and induce HIF-driven reporter gene activity in two different cell types (primary mouse endothelial and HepG2 hepatoma cells). Degradation of HIF-1 alpha occurred mainly in the cytoplasm of HepG2 cells, whereas it occurs with equal efficiency in nuclear and cytoplasmic compartments of primary endothelial cells. Consistent with these observations, green fluorescent protein-HIF-1 alpha is differently distributed during hypoxia and reoxygenation in hepatoma and endothelial cells. Consequently, we propose that differential compartmentalization of degradation of HIF-1 alpha and the subcellular distribution of HIF-1 alpha may account for cell-type-specific differences in stabilizing HIF-1 alpha protein levels under hypoxic conditions.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Carcinoma, Hepatocellular/metabolism
- Cattle
- Cell Compartmentation
- Cell Hypoxia
- Cell Line
- Cells, Cultured
- Endothelium, Vascular/cytology
- Endothelium, Vascular/metabolism
- Gene Products, tat/genetics
- Gene Products, tat/metabolism
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit/genetics
- Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
- Mice
- Models, Biological
- Neovascularization, Physiologic
- Peptide Fragments/genetics
- Peptide Fragments/metabolism
- Proteasome Endopeptidase Complex/metabolism
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/metabolism
- Subcellular Fractions/metabolism
- Von Hippel-Lindau Tumor Suppressor Protein/metabolism
Collapse
Affiliation(s)
- Xiaowei Zheng
- Department of Cell and Molecular Biology, Karolinska Institutet, S-171 77 Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
In eukaryotes, thousands of genes have to be organized and expressed in the cell nucleus. Conformational and kinetic instability of nuclear structure and components appear to enable cells to use the encoded information selectively. The ubiquitin-proteasome system is active in distinct nuclear domains and plays a major role controlling the initial steps of gene expression, DNA repair and nuclear quality-control mechanisms. Recent work indicates that a tuned balance of ubiquitylation and proteasome-dependent protein degradation of nuclear proteins is instrumental in nuclear function and, when deregulated, leads to the development of diseases such as polyQ disorders and other neurodegenerative conditions.
Collapse
Affiliation(s)
- Anna von Mikecz
- Institut für umweltmedizinische Forschung, Heinrich-Heine-Universität Düsseldorf, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany.
| |
Collapse
|
38
|
Chen Y, Dai X, Haas AL, Wen R, Wang D. Proteasome-dependent down-regulation of activated Stat5A in the nucleus. Blood 2006; 108:566-74. [PMID: 16569768 PMCID: PMC1895487 DOI: 10.1182/blood-2005-12-4777] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
A broad spectrum of cytokines can activate the signal transducer and activator of transcription 5 (Stat5) by inducing a single tyrosine phosphorylation of the molecule. Although the process of Stat5 activation has been well studied, the mechanism by which it is inactivated is not fully understood. We demonstrate that the proteasome inhibitor MG132, but not the nuclear export inhibitor leptomycin B (LMB), stabilizes active nuclear Stat5A, whereas MG132 only partially stabilizes active cytoplasmic Stat5A. Importantly, ubiquitinated Stat5A is detected in the nucleus and the polyubiquitination of active Stat5A is K48 linked, a linkage type targeting proteins for degradation. Ubiquitination of Stat5A is recapitulated in a cell-free system, and Ubc5 is identified as the E2-conjugating enzyme for Stat5A ubiquitination. Interestingly, phosphorylation of Stat5A per se is not required for ubiquitination. Finally, C-terminal deletion analysis of Stat5A localizes the amphipathic region of amino acids 751-762 as a ubiquitination signal, possibly representing an E3 recognition motif. Taken together, these results demonstrate that the down-regulation of nuclear and cytoplasmic active Stat5A is differentially regulated. In the nucleus, ubiquitin/proteasome-mediated protein degradation is the dominant mechanism for the down-regulation of active Stat5A, whereas in the cytoplasm, protein tyrosine phasphatase is a major player in the down-regulation of active Stat5A.
Collapse
Affiliation(s)
- Yuhong Chen
- State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, China
| | | | | | | | | |
Collapse
|
39
|
Rockel TD, Stuhlmann D, von Mikecz A. Proteasomes degrade proteins in focal subdomains of the human cell nucleus. J Cell Sci 2005; 118:5231-42. [PMID: 16249232 DOI: 10.1242/jcs.02642] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The ubiquitin proteasome system plays a fundamental role in the regulation of cellular processes by degradation of endogenous proteins. Proteasomes are localized in both, the cytoplasm and the cell nucleus, however, little is known about nuclear proteolysis. Here, fluorogenic precursor substrates enabled detection of proteasomal activity in nucleoplasmic cell fractions (turnover 0.0541 μM/minute) and nuclei of living cells (turnover 0.0472 μM/minute). By contrast, cell fractions of nucleoli or nuclear envelopes did not contain proteasomal activity. Microinjection of ectopic fluorogenic protein DQ-ovalbumin revealed that proteasomal protein degradation occurs in distinct nucleoplasmic foci, which partially overlap with signature proteins of subnuclear domains, such as splicing speckles or promyelocytic leukemia bodies, ubiquitin, nucleoplasmic proteasomes and RNA polymerase II. Our results establish proteasomal proteolysis as an intrinsic function of the cell nucleus.
Collapse
Affiliation(s)
- Thomas Dino Rockel
- Institut für Umweltmedizinische Forschung at Heinrich-Heine-University, Auf'm Hennekamp 50, 40225 Düsseldorf, Germany
| | | | | |
Collapse
|
40
|
Lingbeck JM, Trausch-Azar JS, Ciechanover A, Schwartz AL. E12 and E47 modulate cellular localization and proteasome-mediated degradation of MyoD and Id1. Oncogene 2005; 24:6376-84. [PMID: 16007194 DOI: 10.1038/sj.onc.1208789] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Programs of tissue differentiation are likely controlled by factors regulating gene expression and protein degradation. In muscle, the degradation of the muscle transcription factor MyoD and its inhibitor Id1 occurs via the ubiquitin-proteasome system. E12 and E47, splice products of the E2A gene, interact with MyoD to activate transcription of the muscle program and are also degraded by the ubiquitin-proteasome system (t(1/2) = approximately 6 h). E12 and E47 each contain two regions of basic amino acids, which, when mutated, lead to cytoplasmic accumulation of the proteins. These NLS mutants (E12(NLS), E47(NLS)) are degraded with a half-life similar to the wild-type proteins. In nonmuscle cells, cotransfection of either E12 or E47 with MyoD extended MyoD's half-life from approximately 1 to approximately 4 h. In addition, cotransfection of either E12 or E47 with Id1 led to a marked reduction in Id1's degradation rate from t(1/2) of approximately 1 to approximately 8 h. Furthermore, the cotransfection of NLS deficient mutants of MyoD or Id1 with E12 or E47 resulted in altered intracellular localization of the proteins largely dependent upon the E12 or E47 moiety. Cotransfection of wild-type MyoD or Id1 with NLS deficient mutants of E12 or E47 also led to an altered intracellular localization of MyoD and Id1. These results demonstrate in vivo that E12 and E47 modulate both MyoD and Id1 degradation and may have implications for the physiological regulation of muscle development.
Collapse
Affiliation(s)
- Jody M Lingbeck
- Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA
| | | | | | | |
Collapse
|
41
|
Forcales SV, Puri PL. Signaling to the chromatin during skeletal myogenesis: Novel targets for pharmacological modulation of gene expression. Semin Cell Dev Biol 2005; 16:596-611. [PMID: 16129633 DOI: 10.1016/j.semcdb.2005.07.005] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Cellular differentiation entails an extensive reprogramming of the genome toward the expression of discrete subsets of genes, which establish the tissue-specific phenotype. This program is achieved by epigenetic marks of the chromatin at particular loci, and is regulated by environmental cues, such as soluble factors and cell-to-cell interactions. How the intracellular cascades convert the myriad of external stimuli into the nuclear information necessary to reprogram the genome toward specific responses is a question of biological and medical interest. The elucidation of the signaling converting cues from outside the cells into chromatin modifications at individual promoters holds the promise to unveil the targets for selective pharmacological interventions to modulate gene expression for therapeutic purposes. Enhancing muscle regeneration and preventing muscle breakdown are important goals in the therapy of muscular diseases, cancer-associated cachexia and aging-associated sarcopenia. We will summarize the recent progress of our knowledge of the regulation of gene expression by intracellular cascades elicited by external cues during skeletal myogenesis. And will illustrate the potential importance of targeting the chromatin signaling in regenerative medicine--e.g. to boost muscle regeneration.
Collapse
Affiliation(s)
- Sonia Vanina Forcales
- Laboratory of Gene Expression, Dulbecco Telethon Institute (DTI) at Fondazione A. Cesalpino, ICBTE, San Raffaele Biomedical Science Park of Rome, Rome, Italy
| | | |
Collapse
|
42
|
Sun L, Trausch-Azar JS, Ciechanover A, Schwartz AL. Ubiquitin-proteasome-mediated degradation, intracellular localization, and protein synthesis of MyoD and Id1 during muscle differentiation. J Biol Chem 2005; 280:26448-56. [PMID: 15888449 DOI: 10.1074/jbc.m500373200] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Mammalian skeletal myogenesis results in the differentiation of myoblasts to mature syncytial myotubes, a process regulated by an intricate genetic network of at least three protein families: muscle regulatory factors, E proteins, and Id proteins. MyoD, a key muscle regulatory factor, and its negative regulator Id1 have both been shown to be degraded by the ubiquitin-proteasome system. Using C2C12 cells and confocal fluorescence microscopy, we showed that MyoD and Id1 co-localize within the nucleus in proliferating myoblasts. In mature myotubes, in contrast, they reside in distinctive subcellular compartments, with MyoD within the nucleus and Id1 exclusively in the cytoplasm. Cellular abundance of Id1 was markedly diminished from the very onset of muscle differentiation, whereas MyoD abundance was reduced to a much lesser extent and only at the later stages of differentiation. These reductions in MyoD and Id1 protein levels seem to result from a change in the rate of protein synthesis rather than the rate of degradation. In vivo protein stability studies revealed that the rates of ubiquitin-proteasome-mediated MyoD and Id1 degradation are independent of myogenic differentiation state. Id1 and MyoD were both rapidly degraded, each with a t 1/2 approximately = 1 h in myoblasts and in myotubes. Furthermore, relative protein synthesis rates for MyoD and Id1 were significantly diminished during myoblast to myotube differentiation. These results provide insight as to the interaction between MyoD and Id1 in the process of muscle differentiation and have implications for the involvement of the ubiquitin-proteasome-mediated protein degradation and protein synthesis in muscle differentiation and metabolism under abnormal and pathological conditions.
Collapse
Affiliation(s)
- Liping Sun
- Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri 63110, USA
| | | | | | | |
Collapse
|
43
|
Dufton C, Marcora E, Chae JH, McCullough J, Eby J, Hausburg M, Stein GH, Khoo S, Cobb MH, Lee JE. Context-dependent regulation of NeuroD activity and protein accumulation. Mol Cell Neurosci 2005; 28:727-36. [PMID: 15797719 DOI: 10.1016/j.mcn.2004.12.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2004] [Revised: 12/03/2004] [Accepted: 12/07/2004] [Indexed: 11/29/2022] Open
Abstract
NeuroD/BETA2 (referred to as NeuroD hereafter) is a basic helix-loop-helix (bHLH) transcription factor that is required for the development and survival of a subset of neurons and pancreatic endocrine cells in mice. Gain-of-function analyses demonstrated that NeuroD can (i) convert epidermal fate into neuronal fate when overexpressed in Xenopus embryos, and (ii) activate the insulin promoter in pancreatic beta cell lines in response to glucose stimulation. In glucose-stimulated INS-1 pancreatic beta cells, mutations of S259, S266, and S274 to alanines inhibited the ability of NeuroD to activate the insulin promoter. Phosphorylation of those serine residues by ERK1/2 was required for NeuroD activity in that assay. To determine whether the same residues are implicated in the neurogenic activity of NeuroD, we mutated the conserved S259, S266, and S274 of Xenopus NeuroD to alanines (S259A, S266A, and S274A), and performed an ectopic neurogenesis assay in Xenopus embryos. In contrast to what has been observed in the pancreatic beta cell line, the S266A and S274A mutant forms of Xenopus NeuroD displayed significantly increased abilities to form ectopic neurons, while S259A had little effect. In addition, S266A and S274A of Xenopus NeuroD resulted in increased accumulation of protein in the injected embryos while the corresponding mutations on mouse NeuroD did not have the same effect in an insulinoma cell line. Our results demonstrate that the consequence of NeuroD protein modification is context-dependent at both the molecular and functional levels.
Collapse
Affiliation(s)
- Christopher Dufton
- Department of Molecular, Cellular, and Developmental Biology, University of Colorado at Boulder, Campus Box 347, Boulder, CO 80309-0347, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Boulanger J, Vézina A, Mongrain S, Boudreau F, Perreault N, Auclair BA, Lainé J, Asselin C, Rivard N. Cdk2-dependent phosphorylation of homeobox transcription factor CDX2 regulates its nuclear translocation and proteasome-mediated degradation in human intestinal epithelial cells. J Biol Chem 2005; 280:18095-107. [PMID: 15741163 DOI: 10.1074/jbc.m502184200] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
By having demonstrated previously that p27(Kip1), a potent inhibitor of G(1) cyclin-cyclin-dependent kinases complexes, increases markedly during intestinal epithelial cell differentiation, we examined the effect of p27(Kip1) on the activity of the transcription factor CDX2. The present results revealed the following. 1) p27(Kip1) interacts with the CDX2 transcription factor. 2) In contrast to CDX2 mRNA levels, CDX2 protein expression levels significantly increased as soon as Caco-2/15 cells reached confluence, slowed their proliferation, and began their differentiation. The mechanism of CDX2 regulation is primarily related to protein stability, because inhibition of proteasome activity increased CDX2 levels. The half-life of CDX2 protein was significantly enhanced in differentiated versus undifferentiated proliferative intestinal epithelial cells. 3) Cdk2 interacted with CDX2 and phosphorylated CDX2, as determined by pull-down glutathione S-transferase and immunoprecipitation experiments with proliferating undifferentiated Caco-2/15 cell extracts. 4) Treatment of Caco-2/15 cells with MG132 (a proteasome inhibitor) and (R)-roscovitine (a specific Cdk2 inhibitor) induced an increase in CDX2 protein levels. 5) Conversely, ectopic expression of Cdk2 resulted in decreased expression of CDX2 protein. 6) Of note, treatment of proliferative Caco-2/15 cells with (R)-roscovitine or leptomycin (an inhibitor of nuclear export through CRM1) led to an accumulation of CDX2 into the nucleus. These data suggest that CDX2 undergoes CRM1-dependent nuclear export and cytoplasmic degradation in cells in which Cdk2 is activated, such as in proliferative intestinal epithelial cells. The targeted degradation of CDX2 following its phosphorylation by Cdk2 identifies a new mechanism through which CDX2 activity can be regulated in coordination with the cell cycle machinery.
Collapse
Affiliation(s)
- Jim Boulanger
- Canadian Institutes of Health Research Group on Functional Development and Physiopathology of the Digestive Tract, Département d'Anatomie et Biologie Cellulaire, Faculté de Médecine, Université de Sherbrooke, Sherbrooke, Québec J1H 5N4, Canada
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD Mediated by the SCF (MAFbx) Ubiquitin Ligase. J Biol Chem 2005; 280:2847-56. [PMID: 15531760 DOI: 10.1074/jbc.m411346200] [Citation(s) in RCA: 284] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
MyoD controls myoblast identity and differentiation and is required for myogenic stem cell function in adult skeletal muscle. MyoD is degraded by the ubiquitin-proteasome pathway mediated by different E3 ubiquitin ligases not identified as yet. Here we report that MyoD interacts with Atrogin-1/MAFbx (MAFbx), a striated muscle-specific E3 ubiquitin ligase dramatically up-regulated in atrophying muscle. A core LXXLL motif sequence in MyoD is necessary for binding to MAFbx. MAFbx associates with MyoD through an inverted LXXLL motif located in a series of helical leucine-charged residue-rich domains. Mutation in the LXXLL core motif represses ubiquitination and degradation of MyoD induced by MAFbx. Overexpression of MAFbx suppresses MyoD-induced differentiation and inhibits myotube formation. Finally the purified recombinant SCF(MAFbx) complex (SCF, Skp1, Cdc53/Cullin 1, F-box protein) mediated MyoD ubiquitination in vitro in a lysine-dependent pathway. Mutation of the lysine 133 in MyoD prevented its ubiquitination by the recombinant SCF(MAFbx) complex. These observations thus demonstrated that MAFbx functions in ubiquitinating MyoD via a sequence found in transcriptional coactivators. These transcriptional coactivators mediate the binding to liganded nuclear receptors. We also identified a novel protein-protein interaction module not yet identified in F-box proteins. MAFbx may play an important role in the course of muscle differentiation by determining the abundance of MyoD.
Collapse
Affiliation(s)
- Lionel A Tintignac
- Laboratoire de Génomique Fonctionnelle et Myogénèse, UMR866 Différenciation Cellulaire et Croissance, INRA UM II, Campus INRA/ENSA, 2 Place Pierre Viala, 34060, Montpellier, Cedex 1, France
| | | | | | | | | | | |
Collapse
|
46
|
Viñals F, Ventura F. Myogenin Protein Stability Is Decreased by BMP-2 through a Mechanism Implicating Id1. J Biol Chem 2004; 279:45766-72. [PMID: 15322112 DOI: 10.1074/jbc.m408059200] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Bone morphogenetic protein-2 (BMP-2) induces a switch in differentiation of mesenchymal cells from the myogenic to the osteogenic lineage. Here we describe that in C2C12 cells, BMP-2 decreases myogenin expression induced by des-(1,3) insulin-like growth factor-1 (des-(1,3)IGF-1) or ectopically expressed from a constitutive promoter, even in conditions where myogenin mRNA levels were unaffected. Addition of BMP-2 decreases myogenin protein half-life to 50%, whereas proteasome inhibitors abolish these effects. Forced expression of Id1, either by transient transfection or under the control of an inducible system, causes degradation of myogenin in the absence of BMP-2. In contrast, E47 overexpression blocks the inhibitory effect of BMP-2 on myogenin levels. Finally, expression of E47 in 293 cells stabilizes myogenin, an effect that is dependent on the heterodimerization mediated by their helix-loop-helix. Our findings indicate that induction of Id1 not only blocks transcriptional activity but also induces myogenin degradation by blocking formation of myogenin-E47 protein complexes.
Collapse
Affiliation(s)
- Francesc Viñals
- Unitat de Bioquímica, Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, E-08907 L'Hospitalet de Llobregat, Spain
| | | |
Collapse
|
47
|
Viñals F, Reiriz J, Ambrosio S, Bartrons R, Rosa JL, Ventura F. BMP-2 decreases Mash1 stability by increasing Id1 expression. EMBO J 2004; 23:3527-37. [PMID: 15318167 PMCID: PMC516632 DOI: 10.1038/sj.emboj.7600360] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2004] [Accepted: 07/15/2004] [Indexed: 01/17/2023] Open
Abstract
In neural development, bone morphogenetic proteins (BMPs) restrict neuronal differentiation, thereby promoting the maintenance of progenitor cells or even inducing astrocytogenesis. We report that exposure of neuroendocrine lung carcinoma cells to BMP-2 leads to a rapid decline in steady-state levels of Mash1 protein and some neuron-specific markers. BMP-2 induces a post-transcriptional decrease in Mash1 levels through enhanced degradation. We demonstrate that Mash1 protein stability is tightly regulated by the E47/Id1 expression ratio. Transient induction of Id1 by BMP-2 negatively correlates with Mash1 levels. Furthermore, an ectopic increase in Id1 levels is sufficient to induce degradation of either ectopic or endogenous Mash1, whereas expression of Mash1 in Id1-deficient cells or overexpression of E47 makes Mash1 levels refractory to the addition of BMP-2. Furthermore, we show that the E47/Id1 expression ratio also regulates CK2-mediated phosphorylation of Mash1 on Ser152, which increases interaction of Mash1-E47 heterodimers. We propose a novel mechanism in which the balance between Id and E protein levels regulates not only the transcriptional function but also protein stability of the neurogenic bHLH transcription factor Mash1.
Collapse
Affiliation(s)
- Francesc Viñals
- Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| | - Julia Reiriz
- Departament d'Infermeria Fonamental i Medicoquirúrgica, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| | - Santiago Ambrosio
- Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| | - Ramon Bartrons
- Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| | - Jose Luis Rosa
- Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| | - Francesc Ventura
- Departament de Ciències Fisiològiques II, Campus de Bellvitge, Universitat de Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, Spain
| |
Collapse
|
48
|
Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol 2004; 24:6569-80. [PMID: 15254225 PMCID: PMC444842 DOI: 10.1128/mcb.24.15.6569-6580.2004] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
MEN1 is a tumor suppressor gene that is responsible for multiple endocrine neoplasia type 1 (MEN1) and that encodes a 610-amino-acid protein, called menin. While the majority of germ line mutations identified in MEN1 patients are frameshift and nonsense mutations resulting in truncation of the menin protein, various missense mutations have been identified whose effects on menin activity are unclear. For this study, we analyzed a series of menin proteins with single amino acid alterations and found that all of the MEN1-causing missense mutations tested led to greatly diminished levels of the affected proteins in comparison with wild-type and benign polymorphic menin protein levels. We demonstrate here that the reduced levels of the mutant proteins are due to rapid degradation via the ubiquitin-proteasome pathway. Furthermore, the mutants, but not wild-type menin, interact both with the molecular chaperone Hsp70 and with the Hsp70-associated ubiquitin ligase CHIP, and the overexpression of CHIP promotes the ubiquitination of the menin mutants in vivo. These findings reveal that MEN1-causing missense mutations lead to a loss of function of menin due to enhanced proteolytic degradation, which may be a common mechanism for inactivating tumor suppressor gene products in familial cancer.
Collapse
Affiliation(s)
- Hiroko Yaguchi
- Tumor Endocrinology Project, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
| | | | | | | | | | | |
Collapse
|
49
|
Trausch-Azar JS, Lingbeck J, Ciechanover A, Schwartz AL. Ubiquitin-Proteasome-mediated degradation of Id1 is modulated by MyoD. J Biol Chem 2004; 279:32614-9. [PMID: 15163661 DOI: 10.1074/jbc.m403794200] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Degradation of many short-lived cellular proteins such as the transcription factor MyoD occurs via the ubiquitin-proteasome pathway. MyoD, similar to many rapidly degraded regulatory factors, interacts with several high affinity binding partners, including members of the Id (inhibitors of DNA binding) family. Following transfection to HeLa cells, Id1 is localized to the nucleus and rapidly (t(1/2) approximately 1 h) degraded via the ubiquitin-proteasome system. Mutagenesis of lysine residues within the putative nuclear localization region (amino acids 68-82) directs Id1(NLS) to the cytoplasm yet confers an increased rate of degradation (t(1/2) approximately 0.5 h). Id1 in which all lysine residues were mutagenized to alanine (lysineless Id1) was also rapidly degraded (t(1/2) approximately 0.6 h). Addition of a Myc(6) tag to the N terminus of lysine-less Id1 markedly stabilized Id1 (t(1/2) > 10 h) and suggests degradation via the N terminus-dependent pathway. Co-transfection of MyoD with Id1 or Id1(NLS) increases Id1 or Id1(NLS) within the nucleus and markedly reduces the rate of Id1 or Id1(NLS) degradation. These results thus demonstrate that in vivo MyoD modulates the rate of Id1 degradation and suggest a dynamic interplay of these factors.
Collapse
Affiliation(s)
- Julie S Trausch-Azar
- Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, Missouri 63110, USA
| | | | | | | |
Collapse
|
50
|
Di Carlo A, De Mori R, Martelli F, Pompilio G, Capogrossi MC, Germani A. Hypoxia inhibits myogenic differentiation through accelerated MyoD degradation. J Biol Chem 2004; 279:16332-8. [PMID: 14754880 DOI: 10.1074/jbc.m313931200] [Citation(s) in RCA: 100] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cells undergo a variety of biological responses when placed in hypoxic conditions, including alterations in metabolic state and growth rate. Here we investigated the effect of hypoxia on the ability of myogenic cells to differentiate in culture. Exposure of myoblasts to hypoxia strongly inhibited multinucleated myotube formation and the expression of differentiation markers. We showed that hypoxia reversibly inhibited MyoD, Myf5, and myogenin expression. One key step in skeletal muscle differentiation involves the up-regulation of the cell cycle-dependent kinase inhibitors p21 and p27 as well as the product of the retinoblastoma gene (pRb). Myoblasts cultured under hypoxic conditions in differentiation medium failed to up-regulate both p21 and pRb despite the G1 cell cycle arrest, as evidenced by p27 accumulation and pRb hypophosphorylation. Hypoxia-dependent inhibition of differentiation was associated with MyoD degradation by the ubiquitin-proteasome pathway. MyoD overexpression in C2C12 myoblasts overrode the differentiation block imposed by hypoxic conditions. Thus, hypoxia by inducing MyoD degradation blocked accumulation of early myogenic differentiation markers such as myogenin and p21 and pRb, preventing both permanent cell cycle withdraw and terminal differentiation. Our study revealed a novel anti-differentiation effect exerted by hypoxia in myogenic cells and identified MyoD degradation as a relevant target of hypoxia.
Collapse
Affiliation(s)
- Anna Di Carlo
- Laboratorio di Biologia Vascolare e Terapia Genica, Centro Cardiologico Monzino, Istituto di Ricovero e Cura a Carattere Scientifico, 20138 Milan, Italy
| | | | | | | | | | | |
Collapse
|